Merck’s anti‑TL1A antibody misses SSc‑ILD trial but hits primary endpoints in hidradenitis suppurativa

Merck's anti‑TL1A monoclonal antibody, tulisokibart, was evaluated in two phase 2 studies.

In the systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) trial, the primary endpoint was not met, leading Merck to discontinue the study. No new safety issues were observed.

Conversely, the phase 2b trial in hidradenitis suppurativa (HS) achieved both its primary and key secondary endpoints, and Merck plans to present the data at an upcoming medical meeting.

The company previously reported a phase 3 success for tulisokibart in ulcerative colitis, leaving a clear development path for the asset despite the SSc‑ILD setback.